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Chapter 8
ST]MMARY. CONCLUSIONS AND PERSPBCTTVES
ST]MMARY
Adriamycin (Adr) and cisplatin (CDDP) play an important role in cancer chemotherapy.
However, the frequent occurrence of resistance to these drugs represents a significant problem
in the treatment of patients with cancer. A better understanding of the mechanisms involved in
drug resistance may open ways to circumvent this problem and indicate possible targets for
modulation of drug resistance. This thesis focuses on one of the possible mechanisms involved
in cellular resistance to Adr and CDDP: the availability of cellular detoxifying systems which
may be an important determinant of resistance to Adr, CDDP and other chemotherapeutic
drugs.
In chapter 1 a review is given of the detoxifying systems available for quinone-
containing agents such as Adr, as well as for electrophilic agents such as CDDP. The role of
these mechanisms in drug resistance is presented and possibilities to modulate at the level of
cellular resistance are discussed.
In chapters 2,3 and 4 the role of detoxification of Adr and/or Adr-induced free radicals
in in vitro and in vivo acquired Adr resistance is described. The studies were performed in the
human small cell lung carcinoma cell line GLC. and in a series of in vitro acquired Adr
resistant sublines of this line. In addition, a unique model, consisting of three human small cell
lung carcinoma cell lines established from one patient during clinical follow-up, reflecting in
vivo acquired resistance to combined (chemo)therapy, facilitated the study on in vivo acquired
resistance.
Although still controversial, the mechanism of Adr-induced cytotoxicity appears to be
at least partly linked to its enzymatic reductive activation to a semi-quinone free radical
metabolite with subsequent generation of extremely toxic free radicals. Mechanisms involved
in Adr resistance, however, can be multifactorial, and include enhanced expression of the mdr,
gene (the so-called classic multidrug resistance resulting in increased drug efflux mediated by
a 170 kDa membrane glycoprotein), an increased capacity to detoxify Adr and/or Adr-induced
free radicals, a decreased or altered topoisomerase II and/or an enhanced DNA repair.
In chapter 2 the role of free radicals in Adr resistance, studied in GLCo-Adr, and GLC.-
Adrr, two Adr resistant sublines derived from GLC., is described. GLCr-Adr, had an acquired
Adr resistance factor of 44 after culturing without Adr for 20 days. GLCo-Adrr, the same
subline but cultured without Adr for 3 months, had a decreased but stable resistance factor of
8. Cross-resistance for the free radical inducers hydrogen peroxide (HrOr) and X-ray was
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observed in both resistant sublines. The detoxifying capacity, as measured by the glutathione
(GSH) level and the activities of the enzymes glutathione peroxidase, glutathione S-transferase
(GST), superoxide dismutase and catalase, was not increased in the two resistant sublines,
compared to the sensitive GLC.. In order to evaluate the cause of the reduced cytotoxicity by
the free radical inducers in the resistant cell line, the amount of DNA breaks and DNA break
repair was studied. Adr induced a decreased amount of DNA breaks in GLC,t-Adr, compared
to GLC.. For HrO, and X-ray a comparable amount of DNA damage was found. GLCo-Adr,
was better capable to repair DNA breaks induced by Adr, HrO2 and X-ray than GLC.. No
increased enzyme capacity for the detoxification of free radicals was detected in the cytosol of
the resistant cell lines. The resistance against free radicals in GLCo-Adrt is, at least in part, a
result of increased DNA repair.
Little is known about a similarity between the mechanisms responsible for in vitro
acquired resistance and those operative in the clinic. In chapter 3 a study concerning
mechanisms for in vivo resisiance in three small cell lung carcinoma cell lines GLCr4, GLC16
and GLC,, is described. These cell lines, established from one patient during clinical follow-up,
reflect in vivo acquired resistance to cytostatic drugs and radiation. In short, GLC,a was
derived before therapy. Treatment consisted of cyclophosphamide, Adr, and etoposide. After
an initial complete response, treatment was restarted because of tumor recurrence. A partial
response was seen and therapy was discontinued. At that moment GLCru was derived.
Subsequently radiotherapy was given. After recurrence of disease, GLC,, was established from
a biopsy of the irradiated area. Despite additional treatment, progression was seen. Clinically
the tumor changed from sensitive (GLCr4) to completely resistant (GLCre) during the treatment.
The sensitivity of the patient's tumor at the time GLC,, was developed was not reflected in a
pronounced sensitivity of the cell line for Adr, HrOr, X-ray or CDDP in comparison to the cell
lines established later. GLC,' was significantly more sensitive for Adr and HrO, but more
resistant to X-ray compared to GLC,.. JSB-I antibody, detecting the 170 kDa multidrug
resistance associated glycoprotein, produced definite staining in GLC,u, only minimally staining
in GLC,a and no staining at all in GLCre. Intracellular Adr concentrations were decreased in
GLC,. and GLCre, versus GLC,.. Detoxifying capacity as measured by GSH levels, total
sulftrydryl groups, GST and catalase activity, increased from GLCro to GLCtu to GLC,9.
Incubation with D,L-buthionine-S,R-sulfoximine (BSO), a specific inhibitor of the GSH
synthesis, increased Adr- and CDDP-induced cytotoxicity, whereas X-ray-induced cytotoxicity
remained unchanged. Compared to GLC,. and GLC,', Adr induced a higher amount of DNA
strand breaks in GLC,'. In none of the three cell lines Adr-induced DNA strand breaks could
be repaired. X-ray induced a comparable amount of DNA strand breaks in all three cell lines
but all cell lines were capable to repair this damage. A number of mechanisms, among which
an increased detoxifying capacity, were operative in these cell lines. Some but not all of the
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In chapter 4 a number of agents directed at various targets involved in Adr resistance
were used to investigate possible ways to circumvent Adr resistance in the 75-fold Adr resistant
GLCo-Adrro, a descendent of the earlier described GLCo-Adr, (chapter 2). GLC4-Adre. was
characterized, as GLC4-Adr,, by the absence of P-glycoprotein expression, a reduced
intracellular Adr level, and a reduced topoisomerase II activity compared to the parent GLC..
In contrast to GLCo-Adr,, GLCo-Adrno showed an elevated GSH and total GST activity, after
4 years of continuous exposure to Adr. The increase in total GST activity was due to a raised
amount of GST-n, one of the isoenzymes of GST. The effect on Adr resistance was studied
using BSO, alone or in combination with verapamil (drug efflux inhibitor), docosahexaenoic
acid (membrane lipid domain affector), ethacrynic acid (GST inhibitor), aphidicolin (DNA
polymerase-a inhibitor) or novobiocin (topoisomerase II inhibitor). Apart from BSO, none of
the modulators used separately or in combination with BSO increased Adr-induced cytotoxicity
in the sensitive cell line. In GLC., BSO increased Adr-induced cytotoxicity 1.6-fold. In GLC.-
Adrro, no modulating effect of verapamil, docosahexanoic acid, ethacrynic acid or aphidicolin
alone was observed. BSO and novobiocin caused a 12.9- and 1.S-fold increase in Adr-induced
cytotoxicity, respectively. Combination of each of the modulators with BSO showed an additive
effect of the combination BSO plus novobiocin, decreasing the Adr resistance factor from 75
ïo 2.7. Combining modulators of Adr resistance that are directed to different resistance
mechanisms looks promising in vitro.
In chapters 5, 6 and 7 the role of detoxifying systems for platinum (Pt)-containing drugs
such as CDDP in acquired resistance to CDDP is described. The studies were performed in
GLC. and in a series of in vitro acquired CDDP resistant sublines of GLC.. The study
described in chapter 7 also used the human embryonal carcinoma cell line Tera and the subline
Tera-CP with in vitro acquired CDDP resistance as an additional model of CDDP resistance.
Various in vitro studies have shown that cellular resistance to CDDP usually is
multifactorial. Mechanisms involved include an altered membrane transpofi, inactivation of the
drug by cellular thiols such as GSH or metallothioneins, decreased DNA platination and/or
increased repair of Pt-DNA adducts.
GLC4-CDDP, a CDDP resistant subline, showed a variety of differences compared to
the parent line GLC.. In the study presented in chapter 5, it was determined which of the
resis[ance mechanisms examined correlated with the degree of resistance in three human small
cell lung carcinoma cell lines with different sensitivities to CDDP. GLC. and the sublines
GLC4-CDDP, and GLC.-CDDP,, with resistance factors for CDDP of 3 and 11, respectively,
were used. Next to CDDP, carboplatin was used. No consistency was found between the
resistance factor and the growth pattern, cellular volume, doubling time, antigen expression,
cellular and nuclear Pt content and the level of Pt-non histone chromatin protein binding. A
correlation between the resistance factor and the level of GSH, as well as a tendency for the
level of Pt-DNA formation, the PI-GG adduct (the main Pt-containing intrastrand crosslink) and
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the amount of interstrand crosslinks were found. Therefore these changes may be relevant for
the development of resistance. The findings are compatible with a GSH-induced reduction of
reactive Pt in the resistant cell line resultins in a lower net platination and PI-DNA adduct
formation.
In chapter 6 the specific role of GSH in the resistance to CDDP, as studied in GLC4 and
GLC4-CDDP, is described. In addition to measuring the steady state of GSH, the kinetics of
this defense system were studied by monitoring the GSH status of the cells under continuous
pressure of CDDP. GLCI-CDDP maintained its 2.5-fold elevated GSH level whereas GLC.
rapidly synthesized GSH to about twice its initial level, corresponding to 80% of the GSH level
of GLC.-CDDP. BSO was further used to analyze the role of GSH in the resistance to CDDP.
Pretreatment with BSO increased the CDDP-induced cytotoxicity 2.8-fold in GLC4-CDDP and
1.7-fold in GLC4. In GLC4 no changes in the formation of total PI-DNA, the PI-GG adduct or
interstrand crosslinks were observed after GSH depletion. In GSH-depleted GLCI-CDDP celis,
an increase in the amount of total Pt-DNA and the Pt-GG adduct was found. No signihcant
change in interstrand crosslink formation was confirmed after BSO pretreatment although the
initial decreased formation of interstrand crosslinks was eliminated in GLCa-CDDP when
compared to GLC.. Pretreatment with BSO substantially reduced the repair of Pt bound to
DNA in both cell lines. An increased GSH level and GSH synthesis capacity were demonstrated
in the CDDP resistant cells. The observations after BSO treatment suggest wo roles for GSH
in CDDP resislance: first a cytosolic elimination resulting in less DNA platination, and second
a nuclear effect on the formation and repair of PI-DNA adducts.
The development of acquired resisiance to CDDP and the severity of toxicity associated
with this drug encouraged the development of new non cross-resistant Pt-containing drugs. In
chapter 7 the role of GSH in the effectiveness of and in the resislance to seven Pt-containing
drugs was evaluated in two models of CDDP resistance: a human embryonal carcinoma cell
line, Tera, representing a sensitive tumor in the clinic, and the human small cell lung
carcinoma cell line GLC., representing a initially sensitive tumor in the clinic, as well as their
sublines with in vitro acquired CDDP resistance, Tera-CP and GLC4-CDDP. Five Pt(II) drugs
namely, CDDP, carboplatin, and three Pt drugs recently introduced in clinical studies,
zeniplatin, enloplatin and lobaplatin, as well as two Pt(lV) drugs, iproplatin and tetraplatin were
studied. Continuous incubation revealed complete cross-resislance for carboplatin and
zeniplatin, but less for enloplatin and iproplatin in both models. Tetraplatin and lobaplatin
showed, respectively, partial and complete cross-resistance in GLC.-CDDP but no cross-
resislance in Tera-CP.
Compared to the parent line, GSH levels were l.4-fold and 2.5-fold higher in
respectively Tera-CP and GLC.-CDDP, whereas the GST activity was 1.S-fold higher in Tera-
CP and the same in GLC.-CDDP. GSH levels, but not GST activities, of the four cell lines
correlated with sensitivity to the Pt-containing drugs after continuous incubation. BSO was
further used to investigate a possible causal role of GSH in the resistance to the Pt-containing
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drugs. The involvement of GSH differed between the models and the various Pt-containing
drugs. BSO did not affect the CDDP sensitive Tera, whereas in Tera-CP this modulator
reduced the resistance for the Pt(II) drugs CDDP, carboplatin and zeniplatin. As almost no
cross-resistance was observed after a 4 h incubation for enloplatin, iproplatin and tetraplatin,
no modulating effect of BSO could be expected. Reduction of half of the CDDP resistance in
Tera-CP can be ascribed to BSO-induced GSH depletion. In this model of CDDP resistance the
increased GSH content, probably in combination with the increased GST activity, seems to be
a relevant mechanism, responsible for maximal 50% of the resistance, that is operational for
CDDP and other Pt-containing drugs. In the GLC4/GLC1-CDDP model the role of the increased
GSH as a cause of resistance was less obvious. BSO-induced GSH depletion increased the
sensitivity of the sensitive GLC, line for most Pt drugs tested more effectively than in GLC.-
CDDP. Reduction of resistance was only achieved for CDDP and enloplatin.
Therefore, GSH reflects the sensitivity to Pt-containing drugs and may be a good target
for modulation in the clinic. However, the observation that the involvement of GSH differs
between various drugs and models, makes a general causative role of GSH in the sensitivity
for and/or the resistance to Pt-containing drugs questionable and the effect of modulation with
BSO unpredictable.
CONCLUSIONS ANID PERSPECTIVES
It can be concluded that an increase in the enzyme capacity to detoxify Adr and/or Adr-induced
free radicals is no obligatory step in the early acquisition of Adr resislance, as studied in GLC,,-
Adrt. GLCo-Adrno, a descendent of GLCo-Adr,, possessing a higher level of Adr resistance, on
the contrary, showed an elevated GSH level and total GST activity, due to a raised amount of
GST-z-. Modulation of Adr resisiance in GLCo-Adre. using a panel of clinically applied drugs
directed at different resistance mechanisms, showed that combined modulation of operational
resistance mechanisms is promising in vitro and that this may be feasible in the clinic. Studies
are required to determine whether different resistance mechanisms play a role at various levels
of resistance in order to distinguish relevant mechanisms and, subsequently, to select the
correct modifiers for the clinical situation, in which low levels of resistance are most probably
responsible for insensitivity to chemotherapy. As yet, little is known about a similarity between
the mechanisms found for in vitro acquired resistance and those responsible in the clinic. From
the study performed with GLC,., GLC,' and GLC,, reflecting in vivo acquired resislance to
combined (chemo)therapy it was concluded that not all of the observed changes in mechanisms
for drug resistance correlated with the clinical situation. In this model a positive correlation was
found between the intracellular drug level and the capacity to detoxify electrophilic agents and
drug-induced free radicals and the clinical development of resistance of the tumor. Additional
studies in other well-defïned models of in vivo acquired resislance are needed to find out
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whether these mechanisms are of general importance in the clinical situation.
An increased GSH level and decreased DNA platination seem to be relevant mechanisms
for in vitro acquired resistance to CDDP, as studied in GLC.-CDDP. These findings are
compatible with a GSH-induced reduction of reactive Pt in the resistant cells resulting in a
lower net DNA platination. From our studies it can be concluded that there are two possible
roles for GSH as a mechanism involved in CDDP resistance, namely the already mentioned
cytosolic elimination of reactive Pt resulting in less DNA platination and a nuclear effect on
the formation and repair of DNA platinum adducts. A positive correlation between the cellular
GSH level and the sensitivity to Pt-containing drugs was found for seven Pt-containing drugs
in two models of CDDP resistance. Therefore GSH seems to be a good reflector of sensitivity
to Pt-containing drugs and a good target for modulation in the clinic. However, a general
causative role of GSH in the sensitivity of and/or resislance to Pt-containing drugs remains
questionable as the involvement of GSH differed between the two studied models of CDDP
resistance and the various Pt-containing drugs. The potential value of examining the regulation
of the GSH synthesis, both in vitro and in vivo, by evaluation of "y-glutamyl cysteine
synthetase, the enzyme that catalyzes the controlling (and feed-back inhibiting) step of the GSH
synthesis, as an indicator for clinical prognosis merits further investigation. Also additional in-
vitro experiments with e.g. radioactive labeled GSH in order to study the role of GSH at the
DNA level (GSH-Pt-DNA interactions) should be considered.
Literature data and the results described in this thesis do not exclude a protective effect
of cellular detoxifying systems on Adr- or CDDP-induced cytotoxicity. An increase in the
defense capacity for these drugs, however, does not seem to be an obligatory step in the
development of in vitro resistance. Perhaps more important is the positive correlation of the
capacity to detoxify electrophilic agents and drug-induced free radicals with the clinical
development of resistance. At this moment only limited data are available on this subject. The
resistance to Adr and CDDP is multifactorial, the contribution of the detoxifying systems to
resistance as a whole should therefore be considered in perspective to other operational
resistance mechanisms.
Although the primary mechanisms of action of many anticancer agents are fairly well
understood, including the location of their cellular targets and possible mechanisms of ceilular
resistance, it is as yet unknown which mechanisms are involved in the process of cell death
after treatment with Adr or CDDP. Recently it has become clear that both drugs are able to
induce apoptosis, programmed cell death. Insight in this particular process may also indicate
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In the near future the determination of various parameters (proven to be relevant for
resistance in vitro) in human biopsies, if possible before and after treatment, will hopefully
reveal indicators of chemosensitivity and targets for modulation. So far studies, focused on the
role of detoxifying systems, concentrated on the GSH level per se and the overall GST activity.
Apart from interindividual variations, varying correlations of the GSH level and the GST
activity with tumor response in various tumor types and after different chemotherapy treatments
have been found. In addition, intratumor heterogeneity may contribute to determine
chemosensitivity. Recently a positive correlation between the erythrocyte GSH concentration
and the response to chemotherapy has been reported (1). This study, lacking sufficient clarity
and a rational explanation, was performed in 68 patients with various solid tumors and
receiving conventional chemotherapeutic treatments. A more fundamental study in a well-
defined patient group receiving a standard chemotherapy schedule is needed to prove the
predictive value of erythrocyte GSH for the response to chemotherapy.
Measurement of modulator-specific inhibition in tumor samples frorn patients will have
to be the next goal of studies in the clinic. GSH is, with the available modulator BSO, one of
the most promising targets for modulation of the detoxifying systems. Phase I studies,
combining BSO with melphalan, so far demonstrated GSH depletion to below 20% of the
control in peripheral mononuclear cells and in tumor cells without unacceptable clinical toxicity
(2). A phase I study of thiotepa combined with the GST inhibitor ethacrynic acid described
inhibition of the GST activity ïo 31% of the control values. Myelosuppression was the most
important side effect of this combination (3). Phase II trials are ongoing.
Overall, the multifactorial character of resistance together with the considerable
heterogeneity within one tumor with respect to resistance mechanisms implies that for many
resistant tumor types treatment with one modulator will be insufficient to convert drug
resistance in the clinic. Therefore, in the future clinicians might consider treatment with a
cocktail of modulators, directed at different operational resistance mechanisms (e.g. one of
them directed towards the detoxifying system), in order to overcome drug resistance.
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